### **Overview** Solara Active Pharma Sciences Ltd is a global, pure-play Active Pharmaceutical Ingredient (API) manufacturer headquartered in Bengaluru, India. With over three decades of technical heritage rooted in legacy entities *Strides Shasun Ltd* and *Sequent Scientific Ltd*, Solara specializes in high-value commercial APIs and Contract Research and Manufacturing Services (CRAMS). The company operates six globally compliant manufacturing facilities and one dedicated R&D center, serving over 70 countries with a strong presence in regulated markets including North America, Europe, Japan, South Korea, and the Middle East & North Africa (MENA). --- ### **Core Business Segments** 1. **High-Value Commercial APIs:** - Offers a diversified portfolio of over **60 commercialized APIs** across key therapeutic areas: - Pain management - Anthelmintics - Anti-malarials - Anti-infectives - Anti-convulsants - Anesthetics - Anti-psychotics - Antihyperkalemia - Specializes in **technically complex APIs**, including: - Polymer-based APIs (e.g., Sevelamer Carbonate, Patiromer) - Iron-based APIs - Injectable APIs - High-potent APIs (HPAPIs) 2. **CRAMS (Contract Research and Manufacturing Services):** - Provides end-to-end services from preclinical through commercial manufacturing. - Core offerings: - Contract development & manufacturing - Analytical services - Impurity synthesis - Regulatory support (including DMF filings) - Lifecycle management - Focuses on building partnerships with innovator pharma firms and biotech companies, particularly in North America, Europe, and Japan. --- ### **Strategic Initiatives (FY25 – FY26)** - **Demerger of CRAMS & Polymers Business (FY25 Approval):** - Solara approved the demerger of its **CRAMS and Polymers business** into a separately listed entity, **Synthix Global Pharma Solutions Limited**, incorporated in April 2025. - The Vizag facility will be dedicated exclusively to the CRAMS platform, leveraging its USFDA-approved status and multi-purpose infrastructure. - INR 2,000 million (~$240 million) of debt will be transferred to the new entity, improving the balance sheet of the core API business. - Solara will retain 100% ownership of the new subsidiary pending regulatory and shareholder approvals, aiming to enhance ROCE and ROI for the remaining API business. - **Strategic Pivot from Volume to Value:** - Transitioning from a volume-driven model (e.g., ibuprofen) to a **value-over-volume strategy**, focusing on high-margin, complex, and differentiated APIs. - Deliberately reducing exposure to low-margin, commoditized products like plain ibuprofen. - Despite ibuprofen derivatives contributing ~30% of revenue (21% plain, 9% derivatives), the company is actively expanding capacity for higher-margin non-ibuprofen APIs. - **Operational Turnaround & Margin Recovery:** - Successfully improved financial performance in FY25: - **Gross Margin: 51.5%** (up from negative in FY24) - **EBITDA turned positive at 16.5%** (from -7.1% in FY24) - **Net Debt reduced by ₹223.4 crores (~22%)** - Key drivers: - Cost optimization - Strategic sourcing - Inventory rationalization - Improved capacity utilization (core catalog business at ~65% utilization, with no bottlenecks anticipated for 2–3 years) - **Regulatory Compliance & Quality Excellence:** - All six API facilities are approved by major global regulators, including: - **USFDA** (Ambernath and Vizag cleared with zero Form 483 observations in May 2024 and May 2025 respectively) - **EDQM (EU)** - **PMDA (Japan)** - **MFDS (South Korea)** - **WHO, TGA, KFDA**, and more - The Vizag site holds both a **US DMF approval for ibuprofen (CDE)** and a **CEP from EDQM**, making Solara the only company globally offering ibuprofen from **two independently regulated sites**. --- ### **Manufacturing & R&D Capabilities** - **Facilities & Capacity:** - **6 API manufacturing facilities** located in: - Ambernath, Mangaluru, Mysuru, Puducherry, Cuddalore, Visakhapatnam (Vizag) - Total reactor capacity: **2,673 kiloliters** (expanded from 2,580 KL in 2023) - Capable of handling both **large-volume commodity APIs** and **small-volume specialty APIs**. - Mirrored production capabilities across sites reduce supply chain concentration risk. - **Advanced Chemistry Expertise:** - Specializes in complex processes: - High vacuum distillation - Grignard reactions - Hydrogenation - Halogenation - Lyophilisation - Flow chemistry - Polymer and chiral chemistry - Photochemistry and enzymatic synthesis - **R&D Center:** - **State-of-the-art R&D center in Bengaluru**, supporting over 60 scientists. - Focus areas: - Synthetic and analytical chemistry - Development of generic formulations and complex NCEs - Rapid launch strategies - Supports **10+ active development programs**, including high-value molecules like: - Sapropterin - Sodium Zirconium Cyclosilicate - Sugammadex - Filed **over 95 US DMFs**, with continuous momentum in regulatory submissions. --- ### **Leadership & Governance** - **Promoter:** - **Mr. Arun Kumar** – Founder of Strides Pharma and co-founder of SeQuent Scientific. Instrumental in positioning Solara as a top-tier API player; aims to make it **India’s second-largest API company within four years**. - **Executive Leadership:** - **Mr. Mohan Muthunarayan** – COO & Executive Director, overseeing integrated operations across Puducherry and Vizag. - **Mr. Vishal Mathur** – Chief Business Officer, with extensive P&L leadership in API divisions at Glenmark, Emcure, and Cohance. - **Dr. Hero Velladurai** – Chief Scientific Officer (API R&D), 27 years of experience, contributed to over 50 API commercializations. - Former CEO **Mr. Poorvank Purohit** (appointed Jan 2023) led early turnaround; leadership structure now optimized for CRAMS and API business separation. --- ### **Risks & Mitigation Strategies** | Risk | Mitigation | |------|-----------| | **Product & Customer Concentration:** 84% of sales from top 10 molecules (mainly ibuprofen-related) | - Expanding pipeline (60+ commercial, 10+ in development)<br>- Filing new DMFs and entering new markets<br>- Diversifying CRAMS customer base | | **Regulatory Scrutiny:** Cuddalore site has pending approvals due to legacy Ranitidine NDMA issue | - Submitting data for reclassification<br>- Transferring critical products to alternate DMF sites (Pondy, Vizag) | | **Pricing Pressure from China:** Competition from low-cost Chinese APIs | - Focus on **quality, reliability, regulatory compliance**, and complex products where China has limited presence | | **Currency Volatility:** ~50% of revenue is export-linked | Natural hedge through import-linked raw material costs and active hedging policies |